SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a massive $27 billion AI infrastructure deal with Meta, which significantly bolsters the company's long-term contracted backlog. While the community is debating the impact of a new $3.75 billion convertible debt offering intended to fund this rapid expansion, many remain bullish on the stock's long-term potential due to sustained backing from industry giants like NVIDIA and Microsoft.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing heightened volatility and trading volume as investors position themselves ahead of the upcoming fourth-quarter earnings release and monitor key regulatory milestones. The community is actively debating the company's long-term potential as a provider of nuclear energy for AI data centers versus concerns regarding its pre-revenue status, recent insider selling, and the broader macro-driven rotation out of high-beta speculative equities.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is drawing significant attention following its Nasdaq IPO and volatile market debut, with investors debating the growth potential of its drone autonomy software currently deployed in combat zones.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is experiencing heightened volatility and investor attention following positive Phase 3 clinical data for its Retevmo therapy and reports that the company has built significant inventory ahead of a potential April FDA decision on its oral obesity pill. Meanwhile, the broader community remains focused on the intense competitive landscape between LLY and Novo Nordisk, closely monitoring pricing strategies, new drug delivery formats, and ongoing regulatory scrutiny regarding the compounded weight-loss drug market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to a significant insider purchase of 550,458 shares and a completed capital raise, which the community views as a major vote of confidence in the company's clinical trajectory. Sentiment is currently divided between long-term holders focusing on upcoming Phase 3 milestones and BLA filings, and skeptics who remain concerned about the impact of dilution on shareholder value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing active community discussion as traders monitor potential buyout interest and growth prospects for its MS therapy, BRIUMVI, ahead of the company's upcoming earnings call. Investors are focused on the firm's revenue trajectory, recent long-term clinical data, and the potential impact of share repurchases on stock performance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and heavy trading volume ahead of the upcoming Optical Fiber Communications Conference (OFC), as market participants speculate on potential major partnership announcements and purchase orders. Community sentiment remains polarized between long-term investors tracking institutional accumulation and technical alignment with hyperscale AI hardware, and skeptics voicing concerns over persistent pre-revenue status and reliance on strategic collaborations.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to a preliminary update from its Phase 3 FLAMINGO-01 trial, which revealed an exceptionally low recurrence rate of less than 1% per year in the open-label arm. Investors are heavily discussing the significance of these consistent long-term results, with the community actively speculating on upcoming abstract titles for the AACR annual meeting and potential strategic partnerships or buyouts.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors monitor the appointment of a new CFO and anticipate the potential announcement of a major hyperscaler tenant. While some community members remain skeptical of management's communication and deal timelines, others are optimistic that the company's behind-the-meter energy model will drive significant long-term growth as infrastructure demand for AI continues to rise.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to a significant settlement regarding patent litigation, a move that removes a long-standing legal overhang and shifts market focus toward the company's robust oncology pipeline and combination vaccine potential. Community discussion is heavily focused on the stock's high short interest and the potential for a major strategic partnership or buyout to accelerate future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Jackson highlighted the rising origination, new capital flow, and the tailwinds that are helping the firm propel forward.</li><li>He stated that the company is well-positioned to address any uncertainties arising from the current environment.</li><li>The CEO noted that, given the company's efficiency and profitability, raising the guidance was a natural outcome.</li></ul>Abacus Global Management Inc. (ABL) recently reported an upbeat third quarter, with the results surpassing Wall Street expectations for the tenth consecutive quarter.Abacus Global reported earnings per share (EPS) of $0.24 in the third quarter (Q3), compared to an estimated EPS of $0.18, according to Stocktwits data. Its revenue stood at $63 million during the quarter, compared to a Street estimate of $50.2 million.<a href="https://stocktwits.com/symbol/ABL">Abacus Global shares</a> were up more than 4% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.Stocktwits caught up with CEO Jay Jackson to understand what drove Abacus Global’s Q3 performance, and what lies ahead for the company.We would like to start with your thoughts on Q3 performance, as well as the longevity of the product in the Middle East.We had an incredibly productive Q3. That was our 10th consecutive quarter in a row where we had exceeded earnings expectations related to consensus. So, we're incredibly proud of that. What's interesting about that statistic is that, actually, six of those quarters we beat earnings estimates by over 30%, including Q3, primarily driven by our continued efforts to expand our message and reach new investors and policyholders.We're seeing our origination tick up. We're also seeing new capital coming into the asset. But most importantly, from a market perspective, I think we've also got some wind at our backs. Specifically, around the premise that people are seeking uncorrelated assets. There's almost a flight to safety and other kinds of assets. And this is an uncorrelated yielding product. And now we're starting to see investors really lean into this asset class. I think that's also helping drive our success right now. And we foresee this continuing.The company's business is evolving slightly from a niche life settlement player to the broader alternative asset management and wealth management segments. What’s driving this transformation?I think that was always kind of the natural evolution of our company, which is that we provide a very distinct service initially to policyholders, and that service is helping them monetize or understand the liquidity in their life insurance policy through its current market value.If the number one fear in retirement is running out of money, wouldn't you like to know how long you're going to be in retirement? Right? So, our underwriting is being applied in multiple ways. But in addition to that, institutional asset management firms, banks, etc., have been looking for this kind of yield.How do you plan to sustain this momentum?One, there's a huge amount of excitement around investing in uncorrelated assets. Just look at the price of gold. Gold's what, $4,000 now, right? You could look at alternative assets, whether it's private credit, [they’ve] raised billions. So I think that there's a lot of room to go here, and quite frankly, we're just scratching the surface. Our expectation is that there will be billions and billions of dollars in assets under management with our firm.We expect people to continue seeking this kind of asset, and don't forget that we're the originator. We're the market maker of that asset. So, they have to come to us, and now they're investing directly.Amid this evolution, the company announced a dividend and share buyback. How do you strike a balance between distributing capital and reinvesting in the company's future growth?We felt it was the right time, and the reason was that as we've seen our business evolve, we wanted to reward our shareholders appropriately. If you look at the formula that we put out in our press release, we actually put out a pretty conservative dividend. It's only a little over 20% of our adjusted net income.We have excess capital to deploy, and we took that excess capital and capitalized our shareholders through our recurring revenues. We think that's the right way to conduct ourselves as an alternative asset manager and should be rewarding our shareholders on an annual basis.Regarding the disconnect in valuation, what do you think retail investors and institutions are missing out on?It’s really an education issue, and it's not just institutions; it's retail, it's across the board in understanding that first and foremost, life insurance is an asset. People treat it as something that they never want to use or as a piece of debt. They don't see it, oh, this is just like any other form of private credit. And so that's why that disconnect exists.That education has to start at the core level, and that takes time. We've spent the last three years doing that, and that message is really starting to resonate.We're right at the precipice of what I think is a breakout. And it's coming from institutions, which are really starting to get this business, retail investors who are kind of nodding their heads and saying, "Oh, I really do get this now."What was the driving factor behind raising FY25 net income guidance?I would say the driving factor for us continuing to increase our guidance is predominantly driven by market forces, in a sense. We are [also] becoming more efficient in our underlying business.We run an incredibly efficient and profitable business. And so I think when you look at the raise on our guidance, that was a natural outcome.The average realized gain in Q3 was around 37%, up from 26% in Q2. Is this due to efficiency, or is there another factor driving it? Do you think this is sustainable?I think it's definitely driven by efficiency, but you'll see it vary quarter to quarter. I mean, if you go back a few more quarters, you'll see that number hover between the 20% to 25% range. And I think that this was an exceptional quarter in Q3, partly driven by our efficiencies, partly driven by market factors.There's a lot of uncertainty regarding rates, and people are still not sure if there will be a hard landing or a recession. How are you going to tackle this sort of uncertainty going forward?We're in a great spot for that kind of uncertainty. I mean, consider the asset. We would benefit in two ways. Actually, both sides of our transaction.One, if you're a policyholder and we're in a recession, and you're seeking liquidity, which means you'll look to places that you may not have considered in the past, such as your life insurance policy, to seek liquidity where you haven't done so before. Originations will more than likely tick up during a recession.The second piece that investors seek during a recessionary environment, like a volatile market or a pullback, is uncorrelated assets.What makes you distinct from your competitors, and can you explain the competitive advantage you have?We're the only public company in our entire industry, and that gives us a significant advantage from both a cost of capital and an efficiency perspective. You know we're always driving our growth, because as a public company, you know you're reporting every quarter, and so being innovative is super important.The interview has been edited for clarity and length.<a href="https://stocktwits.com/symbol/ABL">ABL stock</a> is down 18% year-to-date and 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-rise-senate-votes-to-end-government-shutdown/cLPcKrVRE22">Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retirement planning representational image

Exclusive: Abacus Global CEO Jay Jackson Eyes Billions In AUM, Explains How The Company Plans To Bridge The Valuation Disconnect

In an exclusive conversation with Stocktwits, Jackson lays out what drove Abacus Global’s performance, the market opportunity ahead, and what makes the company distinct from its competitors.

ABCGF
Abacus Group - Stapled (Unit, Ordinary Share) - New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest ABCGF News

ABCGFAbacus Group - Stapled (Unit, Ordinary Share) - New